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Traces relative to hERG1 current in HCT116 (A) and HCT8 (B) CRC cells, cultured in standard conditions. Representative traces relative to hERG1 current in HCT116 (A) and HCT8 (B) CRC cells, cultured in standard conditions (n=25). The pharmacological (WAY blockade, 2 µM) and biophysical (activation curve, V 1/2 = -42.8 ± 3.1 mV and dx 7.1± 0.9, n=7) characteristics of hERG1 currents, obtained from at least three experiments, are shown in C. These characteristics are similar to those described in several cancer cell lines (58).
Supplementary Fig. 4 VEGF-A staining of tumor masses derived from mice injected with HEK 293-mock cells and HEK 293 cells overexpressing hERG1 (HEK-hERG1) described in the main text and in Fig. 6A . Cytoplasmic and extracellular staining is evidenced by the black arrows.
VEGF-A staining of tumor masses derived from mice injected with HCT116-PLKO cells and hERG1-silenced HCT116 cells (HCT116-Sh-hERG1) described in the main text and in Fig. 6B and 6C. Cytoplasmic and extracellular staining is evidenced by the black arrows. VEGF-A was measured as % of stained cells/total cells per microscopic field. Six different microscopic fields were evaluated: HCT116-PLKO= 72% ±8; Sh 7.5= 37% ±9, p<0.03.
Ki67 staining of tumor masses derived from mice injected with HCT116-PLKO cells and hERG1-silenced HCT116 cells (HCT116-Sh-hERG1) described in the main text and in Fig.  6B . Ki67 staining, mainly visible as brown signal in PLKO cells nuclei, evidences an incremented proliferation rate in tumors derived from PLKO cells compared to HCT116-Sh-hERG1 masses. Ki67 was measured as % of stained cells/total cells per microscopic field. Four different microscopic fields were evaluated: HCT116-PLKO staining = 72% ± 6; HCT116-Sh-hERG1 staining = 59% ±4. p< 0.026. hERG1 silencing in HCT116-Sh-hERG1 cells was evaluated by RT-qPCR (0,22±0,04 normalized on PLKO value).
hERG1 channels and angiogenesis
Supplementary Information Supplementary Fig. 5 The effect of FOXO1A and FOXO3 inhibition on VEGF-A, HIF-1α and HIF-2α expression in HCT116 cells. mRNA quantification experiments were performed as described in Materials and Methods. Hs_FOXO1A_7 (ID: 2103988, final concentration 25 nM, Qiagen); Hs_FOXO3_1 (ID: 2103989, final concentration 25 nM Qiagen) and AllStars negative control siRNA (final concentration 25 nM, Qiagen) were used for FOXO genes silencing. Transfection were performed using Hiperfect Transfection Reagent (Qiagen) and following the manufacturer's instructions. This supplementary Figure demonstrates that, as mTORC complex, also FOXO proteins are not involved in modulating VEGF-A, HIF-1α, HIF-2α expression in our cellular model.
Supplementary Table 1
Summary of the expression of β1, herg1 mRNA, hERG1 protein, hERG1 current (I hERG ) in CRC cell lines. Mean fluorescence intensity ratios (MFI) relative to β 1 protein expression were calculated by dividing the MFI of each sample labeled with the anti-β 1 antibody and the secondary antibody, by the MFI of the sample stained only with the secondary antibody. hERG1 mRNA expression was measured by RT-qPCR applying the Pfaffl analysis (Pfaffl et al, 2004 ). hERG1 protein expression was calculated by quantitative densitometric analysis of total protein lysates on WB using ImageJ. For each sample the relative density was calculated by the ratio of the densities of hERG1 and α-tubulin. hERG1 current density (I hERG ) was measured in cells cultured in standard conditions (RPMI+10% FCS). VEGF secretion and the presence of VEGF-A receptors 1 and 2 are also indicated. VEGF-A receptors were analyzed by WB using a rabbit polyclonal anti-Flt-1 antibody (Santa Cruz, H-225) and a rabbit polyclonal anti-Flk-1 (Santa Cruz, sc-315), respectively.
Supplementary Table 2
Effects of β 1 stimulation on hERG1 currents. Data are relative to the experiments reported in 
Supplementary Table 3
The effects of α−hERG1 siRNA and shRNA (transiently and stably transfected, respectively) silencing on hERG1 expression in HCT116 cells used in Fig. 2, Fig. 3,  Fig. 4, Fig. 5 . Cells were transfected with the various siRNAs or shRNAs treated with WAY, and RQ-PCR measurements were performed as described in Materials and Methods. Results were normalized on the herg1 expression level of HEK 293 cells and analyzed by Pfaffl method (1). Data are means ± SEM of two separate experiments, each carried out in duplicate. Values reported in the "% inhibition" column were calculated using either siRNA neg ( for α-herg1 siRNA 1, α-herg1 siRNA 2, α-herg1 siRNA 3) or pLKO.1 (for Sh-hERG1) values as reference. Densitometric analysis relative to Fig. 1C, 1D , 1E. Data were analyzed using ImageJ, and graphs were plotted by Microcal Origin 6.0. G). * p<0.05; ** p< 0.02 (Student's t test). 
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Primer sequences used in RT-qPCR experiments.
hERG1A and VEGF-A mRNA quantification by RT-qPCR was performed using 2 µl of cDNA using the 7500 Fast Real Time PCR System and the SYBR Green Master Mix Kit (Applied Biosystems; Foster City CA, USA). The GAPDH gene was used as a standard reference. The primer sequences for hERG1A and GAPDH were the same as those used in 40. The primer sequences for VEGF-A were the same as those used in 2. The relative expression of hERG1A and VEGF-A was calculated with the comparative threshold cycle method. Standard curves were determined using the FLG29.1 cell line cDNA. HEK 293 sample was used as a calibrator for hERG1a expression. 
HIF activity.
The hypoxia responsive element-luciferase reporter gene vector was transfected into the various cancer cell lines with Lipofectamine 2000 along with the pRL-CMV plasmid (Promega) for normalization. After 5 hours, the medium was changed, and standard culture medium was added. Twenty-four hours later, some of the cell culture plates were transferred into a hypoxia chamber (Concept 400, Jouan, Milan, Italy) set at 0.1% O 2 . After an additional 5 hours of incubation, cells were harvested and firefly and renilla luciferase activities were assayed using the Dual-Luciferase Reporter Assay System (Promega) and employing a Lumat LB 9507 single-tube luminometer (Berthold Technologies).
Immunoprecipitation (IP) and Western Blot (WB) experiments.
For IP, total lysates (1.5-2 mg) were subjected to a pre-clearing step consisting of incubation with protein A-Sepharose 4B beads (Sigma-Aldrich) for two hours at 4°C. Thereafter, cell lysates were immunoprecipitated with the appropriate antibody (anti-β1 TS2/16, Biolegend: 5 µg antibody/mg protein; anti-hERG1 N135, Enzo Life Science: 5 µl antiserum/1.5 mg protein). Cells were detached using 5 mM EDTA in PBS and incubated under normoxia in standard culture conditions or on different substrates in the absence or presence of hERG1 (E4031, 40 µM), β1 (anti-B V 7 (α−β1) blocking antibody 14 µg/ml (kindly provided by Prof. P. Defilippi, University of Turin) inhibitors, or NFKB inhibitor VII (Calbiochem, 1µM) until control cells adhered (3-5 hours). For hERG1 detection, WBs were decorated with an anti-hERG1 rabbit polyclonal antibody (C54, Enzo Life Science, dilution 1:1000). Anti-α-tubulin mouse monoclonal (Sigma, dilution 1:500) antibodies were used as loading controls. For pAkt/Akt detection, the anti-Thr 308 pAkt (Santa Cruz, SC-16646, dilution 1:500) and anti-total Akt (Santa Cruz, SC-8312, dilution 1:500) antibodies were used. For β1 detection, an anti-β1 rabbit polyclonal was used (RM12, Immunological Science, dilution 1:1000). For FAK IP, the anti-total FAK antibody was used at a ratio of 1.5 µl antibody/1.5 mg protein. For p85 subunit detection, an anti-PI3 kinase p85 antibody was used (Upstate 06-195, diluition 1:2000) , and the same antibody was used for IP (5 µl antibody/1 mg protein). For p85 phosphorylation, an anti-phosphotyrosine antibody was used (p-Tyr, Santa Cruz Biotechnology, dilution 1:200). Akt activity was evaluated using the Akt kinase assay kit (Cell Signaling Technology), following the manufacturer's instructions and immunoprecipitating 500 µg of total lysates. For HIF-1α, 100 µg of protein extracts were loaded, and WB were blocked using 5% BSA in TBS 0.1% Tween and probed with a rabbit anti-HIF-1α antibody (Cell Signaling Technologies, dilution 1:500) . For mTOR studies, anti-pSK6 and anti-total SK6 antibodies (Cell Signaling Technologies, dilution 1:500) were used. For p53 and NFKB detection, an anti-total p53 (Dako, dilution 1:1000) and an anti-total NFKB p65 (Santa Cruz, sc-109, dilution 1:200) were used.
Immunofluorescence (IF).
The experiments were performed using the following primary antibodies, using an overnight incubation: anti-Akt (Santa Cruz, SC-8312, dilution 1:500), anti-NFKB p65 (Santa Cruz, sc-109, dilution 1:200). Briefly, cells were seeded onto glass slides (when needed, previously coated with fibronectin (100 μg/ml), in RPMI+ BSA). After 3-4 h of incubation, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min at room temperature. After two washes with PBS, cells were permeabilized for 3 min with 0.1% Triton X-100 in PBS and then blocked in PBS, containing 10% Foetal Bovine serum, for 30 min at room temperature. Nuclear/cytoplasmic staining ratios was calculated with ImageJ measuring the corrected total cell fluorescence (CTCF) performing this calculation: CTCF = Integrated density-(Area of selected cell X Mean fluorescence of background readings, as suggested on the website "sciencetechblog.com/.../05/24/measuring-cell-fluorescence-using-imagej". Nuclear and cell periphery staining were considered. Measured were done at least on 30 cells for each condition, taking cells with the size and shape.
Patch-clamp recordings and data analysis.
Extracellular and pipette solutions were prepared as in 42. When needed, the specific hERG blocker WAY (2) was used at 2 µM, and the resulting traces were subtracted from the control traces to obtain the WAY-sensitive currents. The extracellular solutions were delivered through a 9-hole (0.6-mm) remote-controlled linear positioner with an average response time of 1-2 seconds that was placed near the cell under study.
ERG currents were always recorded under conditions of relatively high [K] o (40 mM) to measure currents under optimal signal-to-noise conditions. Pipette resistances were about 5 MΩ. Cell capacitance and series resistance errors were compensated (85-90%) before each voltage clamp protocol was run to reduce the voltage errors to less than 5% of the protocol pulse. Currents were recorded at room temperature by means of an Axopatch 1D (Axon Instruments, USA) using a protocol consisting of a 15-s conditioning phase (0 to -70 mV in 10 mV decrements) followed by a 0.5-s eliciting step at -120, as previously described (42). pClamp 7 (Axon Instruments) and Origin 6.0 (Microcal Inc, USA) software were routinely used during data acquisition and analysis. The steady-state activation curves were obtained by plotting the normalized peak currents at -120 mV versus the conditioning potential according to (3) .
In vivo experiments using mice models. The volume of tumor masses reported in Fig.6C and measured Orthotopic model. HCT116 cells were grown in vitro and harvested as cell suspensions in a physiological salt solution. Eleven nu/nu mice were randomized into control (seven mice) and treated (four mice) groups. After anesthesia and laparotomy, the coecum was exposed and a small volume of cell suspension (2x10 6 ) was injected into the coecum wall, avoiding any leakage. six days after cell inoculation, mice were treated with a physiological solution or with E4031 at 20 mg/Kg per day for twenty-one days. Mice were monitored for three months. Mice were then sacrificed, and tissues were dissected to evaluate the presence of metastases. Mice that died during the three-month period of monitoring were dissected for investigation of the presence of metastases.
Liver Metastases Model. Formation of hepatic metastases by human HCT116 cells was determined using the mouse model described by 4. The mice were examined daily and sacrificed after three weeks from inoculum. Optical images were analyzed with M3 Vision software (Biospace Lab, Paris, France. Briefly, following anesthesia, a small incision was made and the medial aspect of the spleen was exposed. Tumor cells (2x10 6 ) were slowly injected into the medial splenic tip with a 27-gauge needle, raising a visible pale welt. The spleen was gently replaced and the abdominal was closed with suture.The day after cells injection, the spleen was removed to avoid further metastatic dissemination to the liver. Six days after injection, mice were treated with E4031 or with saline (control mice) for two weeks. The mice were examined daily and sacrificed after three weeks from inoculum. To track the HCT116-luc cells, bioluminescent optical imaging was performed at day 13, using Photon Imager system (Biospace Lab, Paris, France) including a cooled charge-coupled device (CCD) camera. Prior to imaging, mice were anaesthetized by intraperitoneal (i.p.) injection of 275 mg/kg Avertin). Bioluminescent image was acquired for a total 3-minutes exposure, in ventral position, 5 minutes after i.p. injection of D-luciferin (150 mg/Kg, XenoLight RediJect D-Luciferin, Caliper Life Sciences, Villepinte, France). Optical images were analyzed with M3 Vision software (Biospace Lab, Paris, France).
Livers from animals sacrificed three weeks after cell injection and two weeks after the beginning of pharmacological treatment were analyzed for VEGF-A staining and all necrotic areas were excluded and % of stained cells/total cells per microscopic field were
